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Abstract
Anxiety-like responses to stress are accompanied by elevation of brain cytokine-mRNAs. Because
cytokines microinjected into central-amygdala (CeA) substitute for stress in a behavioral
paradigm, the possibility was raised that cytokines increased by stress influence behavior by
affecting CeA-neural activity. Previously, cytokines increased firing-rate of CeA-neurons
comparable to that induced by corticotropin-releasing factor (CRF). In this investigation, tumor-
necrosis-factor-α (TNFα) increased amplitude, but not frequency of mEPSCs from CeA-neurons.
Additionally, TNFα decreased the threshold for triggering action potentials from CeA-neurons
without altering membrane-properties during current-clamp recording. Glutamate-receptor-
antagonist blockade of mEPSCs and the TNFα-induced reduction in firing threshold implicated
glutamate in these changes. A phosphatidyl-inositol-3-kinase-antagonist prevented the TNFα-
induced increased in amplitude of mEPSCs, documenting a TNFα intracellular influence.
Additionally, TNFα increased frequency, but not amplitude of mIPSCs. CRF-receptor-antagonists
were found to prevent the TNFα-induced increase in mIPSC-frequency, without altering the
TNFα-induced amplitude increase in mEPSCs or the reduced threshold for action-potentials by
TNFα. To clarify how TNFα was increasing CRF-release in the presence of tetrodotoxin, the
possibility tested was whether preventing glial-activation would prevent this elevated mIPSC-
frequency blocked by CRF-receptor antagonists. Minocycline, which blocks glial activation,
prevented the TNFα-induced increase in mIPSC-frequency—a finding consistent with glia
contributing to the CRF-involvement in this TNFα action. To fully understand the means by
which a CRF1-receptor-antagonist and minocycline prevent TNFα from increasing mIPSC-
frequency will require further clarification. Nonetheless, these data provide convincing evidence
that release of TNFα by stress could influence GABA- and glutamate-function to alter neural
activity of CeA-neurons.
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1. INTRODUCTION
Cytokines are elevated in brain following restraint stress (Porterfield et al., 2011), social
defeat stress (Wohleb et al., 2011), withdrawal from chronic alcohol exposure (Whitman et
al. 2013,) and following systemic lipopolysaccharide (LPS) administration (Qin et al., 2007;
Whitman et al. 2013). Stress and withdrawal from chronic alcohol are known to be
accompanied by anxiety- and depressive-like behaviors (Dunn et al., 1999; Breese et al.,
2004, 2005ab, 2011; Hammen, 2005; Lindqvist et al., 2009). In addition to the role of
cytokines in immune function, there is a contention that cytokines may produce functional
changes by being neural mediators in the CNS (Adler et al., 2006; Rostène et al., 2007;
Vitkovic L et al., 2000). Evidence supporting cytokines having neural action came in part
from finding the presence of cytokine receptors on neurons (Boka et al., 1994; Hermann et
al., 2004; Holmes et al., 2004). Furthermore, various studies in brain have demonstrated that
cytokines can influence neural function (Belkouch et al., 2011; Churchill et al., 2008;
Callewaere et al., 2006; Emch et al., 2000, 2001; Gruol and Nelson, 2005; Kawasaki et al.,
2008; Knapp et al., 2011; Lukats et al., 2005; Oh et al., 2003; Santello and Volterra, 2012;
Stellwagen et al., 2005, 2006; Tabarean et al., 2006; Wilkinson et al., 1993).
To explore if brain cytokines released by stress could be linked to function,
intracerebroventrical (ICV) administration of cytokines was established to substitute for the
initial two withdrawals of a chronic-intermittent alcohol (CIA) exposure protocol that
facilitated ethanol-withdrawal-induced anxiety (Breese et al., 2008, 2011), just as observed
previously with stress (Breese et al., 2004). The central nucleus of the amygdala (CeA) has a
known association with stress-induced negative affect (Huang et al. 2010). Therefore, to
explore if the CeA could be involved in the ICV cytokine facilitation of ethanol-withdrawal
anxiety (Breese et al., 2008), cytokine microinjection into the CeA prior to ethanol at weekly
intervals was also found to facilitate ethanol withdrawal-induced anxiety-like behavior
(Knapp et al., 2011). Importantly, other investigations have provided indirect evidence for
cytokine action in the CeA being capable of influencing neural activity. Inagaki et al. (2012)
found that increasing cytokines in individuals with an LPS challenge induced an fMRI
change in the amygdala. Prager et al. (2012) recently noted changes in electrophysiological
measures as well as altered cFos levels in amygdala being induced by systemic LPS. More
directly relevant, the proinflammatory cytokine, tumor-necrosis-factor-α (TNFα), applied to
CeA neurons was found to increase firing rate and facilitate GABA release (Knapp et al.,
2011). In spite of these published observations, evaluations of other neural actions of
cytokines in the CeA have not been provided.
Therefore, based upon stress increasing TNFα and other cytokines in brain, the present
investigation defines whether TNFα application to CeA neurons influences selected
electrophysiological determinations, including measures of membrane properties, sensitivity
to current application, mEPSCs, and mIPSCs. First, the possible influence of TNFα on
glutamate-related changes from CeA neurons was tested. Subsequently, the increased
frequency of mIPSCs from TNFα-responsive neurons was confirmed (Knapp et al., 2011).
Then, studies explored the potential mechanisms by which TNFα-induced alterations in
CeA-neural activity. These investigations included exploring if TNFα-induced alterations
depended upon CRF (Knapp et al., 2011), selected kinases (Stellwagen et al., 2005) and/or
glial elements (Behan et al., 1995; Giuliani et al. 2005; Nutile-McMenemy et al., 2007; Tian
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and Bishop, 2003; Yan et al. 2008). Thus, the present efforts not only will provide further
evidence that cytokines affect CeA neural function, but also will explore the means by
which CeA-neural function can be associated with TNFα-induction of glutamate and GABA
activity. Such extended information concerning actions of cytokines on CeA neurons is
expected to further our understanding of the relationship stress-induction of cytokines in this
brain site has to facilitation of anxiety-like behavior that follows stress (Breese et al., 2004,
2008, 2011; Knapp et al., 2011).
1. Materials and Methods
Slice Preparation
Coronal brain slices, 350–400 μm thick, containing the right or left amygdala, were obtained
from 18–24 day-old Sprague-Dawley rats. Animals were lightly anesthetized by isoflurane
inhalation and killed by decapitation. Brains were rapidly removed and placed in ice-cold
sucrose buffer with the following composition (in mM): sucrose 112.5, NaCl 63, KCl 3,
NaH2PO4 1.25, CaCl2 0.5, NaHCO3 24, MgSO4 6, and glucose 10. The solution was aerated
with 95% O2 and 5% CO2. The brain was blocked using a stainless steel blade and
maintained in the ice-cold sucrose buffer until tissue slices of 350–400 μM thickness were
cut from the tissue blocks with a vibrating tissue slicer (Leica VT 1000S). The slices were
stored in a beaker containing artificial cerebrospinal fluid (ACSF) gassed with 95% O2/5%
CO2. ACSF contained (in mM): NaCl 124, KCl 3.25, KH2PO4 1.25, CaCl2 2, NaHCO3 20,
MgSO4 2, and glucose 10. The brain slices were equilibrated at least 1 hour at room
temperature (21–24°) before initiating experiments.
Electrophysiological Recording
Whole-cell patch clamp recording was obtained with an Axopatch 1D amplifier (Axon
Instruments) at room temperature (21–24°). A slice was placed at the bottom of a chamber
attached to a microscope (BX51WI, Olympus; Tokyo, Japan). The slice was superfused with
ACSF gassed with 95%O2/5%CO2 at a flow rate of 1.5 ml/minute Recording electrodes
were pulled from borosilicate glass (Drummond Scientific Company, Broomall, PA) that
had a resistance of 2.5–3 MΩ. The electrodes were filled with internal solution with the
following composition (in mM): KCl 150, HEPES 15, K-ATP 2, EGTA 5, and
phosphocreatine 15 (pH 7.4, adjusted with KOH). For voltage clamp recording the holding
potential was −60 mV. Data were digitized at 5 kHz, and collected with pClamp 10 (Axon
Instruments). Various drugs were placed in sealed syringes containing either a control
(ACSF) or a ACSF solution that were delivered through Teflon tubing connected to a
multibarrel perfusion pencil (250 μM in diameter) positioned 150 to 250 μm from the cell
tested. In both the mIPSC and the mEPSC recordings, 1 μM tetrodotoxin (TTX, Sigma) was
included in the perfusion solution (ACSF) to block action-potential-dependent currents. To
record mIPSCs, 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, Sigma-Aldrich) and
50 μM 2-amino-5- phosphonovaleric acid (AP-5, Sigma-Aldrich) were applied to neurons
prior to recording to block glutamate mediated transmission. For mEPSCs recording, 20 μM
bicuculline methiodide (Tocris) was applied prior to recording to block GABAA receptor
mediated transmission.
The central-amygdala (CeA) was visualized using infrared illumination under differential
interference contrast optics with a water-immersion lens (40x). The image was displayed on
a monitor via video camera to permit the location of neurons in the CeA. After breaking the
neural membrane of a cell, 5- to 7-minutes were required for membrane stabilization, at
which time recordings were immediately initiated. When control recordings were complete,
TNFα or other experimental combinations were administered and recordings made after 5
minutes of drug delivery. Then, a 5–8 minute wash out was followed by a final minute of
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recording. In circumstances in which recovery from TNFα did not occur within the washout
period, sham experiments were performed by replacing TNFα with ACSF or ACSF with
bovine serum albumin (BSA; the carrier for TNFα).
For the current clamp recordings, pre-test potential was maintained at −60 mV by injecting
current that was altered in some cases just before application of current steps to insure that
all measures were made at −60 mV. When injected current was altered, the change in current
required to maintain membrane potential at −60 mV was determined for drug and control
groups. To evaluate whether drug application altered membrane properties, resting
potentials and input resistance before and during drug application were determined. To
measure input resistance, 4 steps of hyperpolarizing current pulses (500-ms, 1 Hz with 0.1
nA increments) from pre-test membrane potential of −60 mV were applied. Input resistance
was calculated as the slope of the current-voltage plot. To evaluate sensitivity of cells to
cytokines, a series of 600-ms current injections (10 steps, 1 Hz) of increasing currents were
applied at given increments to induce action potentials. Current increments were adjusted for
each neuron to insure reaching the threshold for the initiation of action potentials. Once
established, the current increments remained constant for a given neuron. The firing
threshold was defined as the shift of potentials from pre-test membrane potential to the
potential which initiated the action potentials (Figs. 2A & 2B). In the current-clamp
experiments, unless indicated in text, inhibitory receptor antagonists, blockers of excitatory
transmission, and tetrodotoxin (TTX) were not included.
Drugs—NBI 27914, astressin 2B and α-helical CRF 9–41 were supplied by Tocris. The
second messenger inhibitors for PI-3-kinase and P38-MAP-kinase were supplied by Tocris.
TNFα (Recombinant rat TNFα, R&D Systems) was dissolved in 0.1% bovine serum
albumin (BSA) in PBS (10 μg/ml) as a stock solution. In respect to the relevance of the
doses of TNFα (30 to 60-ng/ml) utilized compared to the concentration at the receptor site is
an unknown. TNFα levels in brain have been shown to be in the general range of 0.1- to 1.0-
pg/ml. However, TNFα is released from glia by vesicular transport just as neurotransmitters
are released from neurons. Consequently, the concentration of TNFα at the release site that
acts on the TNFα receptor would be higher than in tissue. Regardless, the TNFα
concentrations used will be shown to influence neural function.
Data Analysis
The data recorded with patch-clamp were analyzed with either Clampfit (pClamp 10, Axon
Instruments) or mini Analysis (Synaptosoft, version 6.0.7). Numerical data were given as
mean ± SEM, and n represents the number of cells tested. Data were submitted to either
analysis of variance (ANOVA) followed by an LSD test or a Student’s t-test as appropriate.
Linear trend was analyzed using a Pierson product moment correlation. Calculated p-values
of less than 0.05 were accepted as evidence of significance.
3. Results
3.1. Effect of TNFα on mEPSCs from CeA-Neurons
This first investigation determined whether TNFα would alter mEPSC characteristics from
CeA neurons. In Fig. 1, the TNFα was found to increase the amplitude of mEPSCs. In Fig.
1A, representative current traces of mEPSCs were recorded from the same CeA neuron prior
to (control) and during 60-ng/ml TNFα application (TNFα) to demonstrate that TNFα
increased the amplitude of mEPSCs. Additionally included in Fig. 1A is a representative
trace that the combination of CNQX and AP-5 blocked the mEPSCs that were recorded
from a CeA neuron in the absence of TNFα (see Fig. 1 legend), an indication that the
recorded mEPSCs resulted from glutamate release. Fig. 1B shows an averaged trace of
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mEPSCs from the representative neuron in Fig. 1A in the presence and absence of TNFα to
demonstrate the increase in mEPSC-amplitude by TNFα (60-ng/ml). Further, Fig. 1C
provides statistical confirmation that the mEPSC amplitude increase by TNFα is dose-
related with a significant linear trend [r (29)=0.74; p<0.05] [F (4,24)=12.30, n=5–8;
p<0.0001]. A Post hoc LSD test demonstrated that the percent increase in mEPSC amplitude
induced by 30 and 60-ng/ml TNFα was significantly greater than the change induced by 0, 6
and 18-ng/ml TNFα (Fig. 1C). Importantly, TNFα (Fig. 1D) did not change the rate of the
mEPSCs [F (4,26) = 0.22, p>0.05; n=5–8]. Because the effect of TNFα on the amplitude of
mEPSCs did not recover during wash out, sham experiments were performed with ACSF,
data which are shown as a “0” TNFα concentration in Figs. 1C and 1D. Adding BSA, the
carrier protein for TNFα, to ACSF (BSA+ACSF) had no effect on percent change in the
amplitude or frequency of mEPSCs compared to ACSF alone (2.4 ± 2.4 t=0,072; p>0.05 and
1 ± 7.4; t=0.078, p>0.05, respectively; n=5). In summary, these results are consistent with
TNFα inducing a change in post-synaptic sensitivity to glutamate without a change in
presynaptic release probability.
3.2 Effect of TNFα on CeA-Neural Membrane Properties and Sensitivity to Current
Application
Because TNFα can increase firing rate (Knapp et al., 2011), the effect of TNFα was tested
on membrane properties to determine if a change in this measure could be responsible for
this increased rate. However, TNFα (60 ng/ml) did not change resting membrane potential
[(control = −59.6 ± 2.9 mV; TNFα = −57.6 ± 3.0 mV; n = 7; t (6) = 1.63; p > 0.05]. Further,
input resistance in controls (63.7 ± 5.6 MΩ) was not significantly altered during application
of 60 ng/ml TNFα (58.8 ± 2.4 MΩ) [n = 6; t(5) = 0.90; p > 0.05]. Results indicate that these
membrane properties were not changed by TNFα suggesting that these changes in neural
resting membrane properties were not responsible for the TNFα increased rate of firing
(Knapp et al., 2011). Because TNFα did not affect the resting membrane properties, the
effect of TNFα (60-ng/ml) was tested on the threshold for initiating an action potential with
current injection. Pre-test membrane potential of −60 mV was maintained by injecting 8.8 ±
5.4 pA prior to TNFα application (n=7). This current was not significantly changed for pre-
test following TNFα (8.0 ± 5.0 pA [t(6)=0.55; p>0.05), consistent with the lack of an effect
of TNFα on both resting membrane potential and input resistance, as shown above. When a
current-step reached a threshold or beyond, single or multiple (2–8) action potentials were
evoked. The mean increment for each current step was 0.12 ± 0.02 nA (n=7).
Under control conditions and in the presence of TNFα, Figs. 2A and 2B illustrate
representative current traces in which TNFα reduced the current required to induce spiking.
Fig. 2C demonstrates statistically that TNFα (60-ng/ml) significantly lowerd the current
threshold required to initiate an action potential [t(6)=3.02; p<0.05; n=7]. Fig. 2D
establishes that a combination of glutamate receptor antagonists [CNQX (10 μM)] and
NMDA [AP-5 (50-μM)] completely blocked the TNFα (60-ng/ml)-induced decrease in
threshold required to elicit an action potential [t(5)=0.93; p>0.05; n=6], a finding indicative
that glutamate is involved in this neural change by TNFα. The solvent for TNFα (BSA) did
not significantly alter the current threshold to trigger action potentials [control=0.21 ± 0.06
nA; BSA=0.23 ± 0.0.04 nA (t (5)=0.542; p>0.05, n=6)].
3.3. Testing of Selected Second-Messenger Antagonists on the TNFα-Induced Increase in
the Amplitude of mEPSCs from CeA Neurons
Stellwagen et al. (2005) demonstrated that TNFα increased the amplitude of mEPSCs from
hippocampal neurons through a phosphatidyl-inositol-3-kinase (PI-3-K)- dependent process,
without finding involvement of several other kinases. Based upon this latter observation
(Stellwagen et al., 2005), the PI-3-kinase inhibitor (wortmannin) and the p38-MAP-kinase
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inhibitor (SB 202190) were tested against the TNFα-induced increase in mEPSC-amplitude
from CeA neurons.
Wortmannin (1-μM) incubation for 30 min to block PI-3-kinase activity abolished the
increased mEPSC-amplitude induced by TNFα (Fig. 3; n=6). Percent change in amplitude
of mEPSCs by TNFα alone (24.3 ± 7.2%; n=7) was significantly greater than that induced
by TNFα when incubated with the wortmannin (1.9 ± 4.3 %; n=6) [post hoc LSD test,
p<0.05; F(2,16)=5.07; p<0.05 for all treatments in Fig. 3]. The wortmannin solvent (0.1%
DMSO) had no effect on the percent increase in the mEPSC amplitude by TNFα [DMSO +
TNFα=22.7 ± 7.6% (n=6); TNFα alone=24.3 ± 7.2%; (n=7); p>0.05 post hoc LSD test)].
The SB 202190 (500-nM) incubation for 2 hours did not change the increase in amplitude of
the mEPSCs by TNFα (60-ng/ml) (13.3 ± 1.5 pA for control; 17.0 ± 1.1 pA for TNFα)
[t(4)=3.01; p<0.05]. Thus, in accord with the TNFα findings by Stellwagen et al. (2005)
from hippocampal neurons, the PI-3-K-antagonist, wortmannin, prevented the TNFα-
induced increase in amplitude of mEPSCs from CeA neurons, without the P38-MAP-kinase-
inhibitor, SB 201190, having an effect.
3.4. Effect of TNFα on mIPSCs from CeA Neurons
In confirmation that TNFα increases GABA-release from CeA neurons (Knapp et al., 2011),
Fig. 4A illustrates that the mIPSCs were completely blocked by bicuculline, a finding
indicative that this TNFα-induced increase in mIPSC-frequency is caused by elevated
GABA release. Fig. 4B further demonstrates that this increase in mIPSC frequency by
TNFα [F (4,33)=3.06; p<0.05; n=5–10] is dose-related with a significant linear trend [r
(38)=0.51; p<0.05]. A post- hoc LSD test showed that the percent increase in mIPSC
frequency by the 60-ng/ml concentration of TNFα was greater than that induced by 0 and 6-
ng/ml of TNFα (Fig. 3B). Fig. 4C illustrates that the amplitude of mIPSCs was not affected
by TNFα [F(4,30)=0.44; p>0.05; n=5–10]. Because the effect of TNFα on mIPSCs did not
recover during the 5-min wash out, sham experiments were conducted with ACSF, which is
shown as the “0” TNFα concentration in Figs. 4B & 4C. Percent changes in frequency and
amplitude of mIPSCs after BSA addition to the ACSF was −3.0 ± 2.6%; t=0.86, p>0.05 and
0.8 ± 6.1%; t=0.078, p>0.05 respectively (n=4), indicating that BSA alone had no effect on
either frequency or amplitude of mIPSCs. These results are consistent with TNFα increasing
the release probability of GABA without affecting synaptic sensitivity to GABA.
3.5. Effect of CRF-Receptor-(CRFR) Antagonists on TNFα Changes in mIPSCs, mEPSCs
and Sensitivity to Current Application
Knapp et al. (2011) reported that a CRF-receptor-antagonist prevents the repeated cytokine
facilitation of ethanol withdrawal-induced anxiety, providing a potential association of CRF
with cytokine and neural function. Previous work has demonstrated that like TNFα (Knapp
et al., 2011), CRF can increase the frequency of mIPSCs (see Roberto et al., 2010). Based
upon the comparable increases in neural firing (Inagaki et al., 2012) and frequency of
mIPSC induced by both CRF and TNFα, studies were undertaken to determine if CRFR-
antagonists would influence the increased frequency of mIPSCs induced by TNFα.
In Fig. 5A, the increased frequency of mIPSCs induced by 60-ng/ml of TNFα (p<0.01
compared to control sham) was blocked by 1 μM of α-helical-CRF (αHCRF), a general
CRFR-antagonist (p<0.001) compared to TNFα alone [F(2,20)=9.89, p<0.01; for all groups,
n=6–8]. In Fig. 5B, CRFR-antagonists that selectively blocked either CRF1Rs or CRF2Rs
were tested against this increased frequency of mIPSCs by TNFα. While the CRF2R-
antagonist (AST=astressin-2B; 100-nM) was without effect (p>0.05; n=7), the CRF1R-
antagonist (NBI=NBI27914; 500-nM) blocked the increased frequency of mIPSCs by TNFα
(Fig. 5B; p<0.05; n=7), just as did the general CRFR-antagonist (αHCRF; Fig. 5A). NBI
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27914 alone had no significant effect on the percent change in frequency of mIPSCs from
CeA neurons, which was −4.3 ± 7.2% (n=5). Representative mIPSCs tracings for control,
TNFα and TNFα with NBI-27914 are shown in Figs. 5C & 5D.
In Fig. 6A, TNFα (30 ng/ml) was confirmed to decrease the threshold for injected current to
elicit an action-potential [t(6) = 3.34; p < 0.05; n = 7]—a change which was not blocked by
1-μM of the general CRFR-antagonist [αHCRF; (t (9)=2.57; p<0.05; n=10) Fig. 6B].
Furthermore, the increased amplitude of mEPSCs induced by TNFα was also not affected
by the general CRFR-antagonist, αHCRF (Figs. 6C & 6D).
3.6. Effect of Minocycline on CRF Involvement in the TNFα-Induced Increase in the
Frequency of mIPSCs from CeA Neurons
The involvement of CRF in the increased frequency of mIPSCs by TNFα was unexpected
given that recording was in the presence of tetrodotoxin—a compound which prevents
neural transmission. However, astrocytes are reported to contain CRF (Tian and Bishop,
2003) and CRF-binding protein (Maciejewski et al., 1996; McClennen and Seasholtz 1999).
Furthermore, Ubink et al. (2003) reported that many other peptides and peptide mRNAs are
present in astrocytes. Therefore, an experiment was initiated to determine if glial elements,
which contain TNFα-receptors (Yan et al., 2008), could be releasing CRF.
Based upon minocycline being able to attenuate microglial (Giuliani et al. 2005;
Nikodemova et al. 2007; Nutile-McMenemy et al., 2007) and astrocytic activity (McAllister
and Miller, 2010), minocycline was tested to determine if the TNFα-induced increase in
frequency of mIPSCs would be prevented. Fig. 7 shows that the TNFα-induced increase in
mIPSC frequency after minocycline (60-μM) incubation for 1-hr was significantly decreased
[(F(2,24)=4.17); n=7–13; p<0.05 with post hoc LSD test]. Minocycline (60 μM) incubation
alone for 1-hour had no effect on the frequency of mIPSCs (i.e., percent change in frequency
of mIPSCs was 9.80 ± 8.67%) (Fig. 7). Thus, TNFα-induced release of CRF from glial
elements might underlie the apparent involvement of CRF suggested by the CRF-receptor
antagonists blocking the TNFα-induced increase in frequency of mIPSCs.
Discussion
Because restraint stress (Porterfield et al., 2011; Whitman et al., 2013) and social defeat
stress (Wohleb et al., 2011) increase cytokine-mRNAs in brain, this investigation of neural
actions of TNFα on CeA neurons was undertaken because the CeA has a known
involvement in stress-induced negative affect (Breese et al., 2004, 2011; Knapp et al., 2011;
Koob, 2008). Initially, TNFα was found to increase the amplitude of mEPSCs, without
affecting mEPSC frequency of CeA neurons—comparable to the earlier reports that TNFα
increased the amplitude of mEPSCs from hippocampal neurons (De et al., 2003; Stellwagen
et al., 2005). Even though TNFα was without an effect on membrane properties, TNFα was
found to reduce the injected current required to induce spiking. This capacity of TNFα to
reduce the current injection necessary to initiate action-potentials in the absence of an
influence on membrane properties was unexpected. Importantly, the glutamate antagonist
cocktail (CNQX + AP-5) not only prevented the effectiveness of glutamate at the synapse,
but also blocked the TNFα-induced reduction in current required to initiate action potentials.
Thus, the decreased current threshold for eliciting a spike appears to be glutamate-
dependent. Because TTX was absent during the spike-threshold determination, TNFα could
have this glutamate-dependent effect by increasing the effectiveness of glutamate
neurotransmission at either the local synapse or at a distant site. Thus, the mechanism by
which TNFα alters the current threshold for production of an action-potential needs further
study.
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Because both AMPA and NMDA receptors were blocked by the antagonist cocktail, either
receptor type could be involved. However, NMDA currents have extremely slow rise-times
(6–10 ms; Naylor et al.,2013) compared to AMPA currents (See Fig. 1B) and would not
likely contribute to the TNFα-induced increase in the amplitude of the mEPSC. Regardless,
this latter finding associated with glutamate is consistent with the earlier demonstration that
TNFα increased firing of CeA neurons (Knapp et al., 2011). Because the frequency of
mEPSCs was not increased, the most likely explanation for the increased amplitude of the
mEPSCs by TNFα was a direct TNFα action on the neuron to increase the number of
glutamate-receptors on the cellular membrane at the synapse (Collingridge et al., 2004;
Heine et al., 2008; Rainey-Smith et al., 2010; Santello and Volterra, 2012; Stellwagen et al.,
2005). In support of this increased amplitude of mEPSCs by TNFα being due to receptor
trafficking, Beattie et al. (2002) demonstrated that glial TNFα induced surface expression of
AMPA receptors on neurons—a finding supported by Stellwagen et al. (2005) who
demonstrated directly that TNFα increased AMPA-receptor number on hippocampal
neurons. One explanation for the TNFα-induced increase in amplitude of mEPSCs from
CeA neurons would be an intracellular activation of a second messenger that would allow
AMPA receptors to pass to the cell surface. In support of this supposition, Stellwagen et al.
(2005) found that the TNFα-induced increase in amplitude of mEPSCs was dependent upon
AMPA receptor transfer to the cell surface by a phosphatidylinositol-3-kinase (PI-3-K)-
dependent process. To assess if the TNFα-induced increased amplitude of mEPSCs from
CeA neurons was also related to this second messenger system, a PI-3-K antagonist and a
P38-MAP-kinase inhibitor were tested against the TNFα-induced increase in the mEPSC
amplitude from CeA neurons. In agreement with TNFα results from hippocampal neurons
(Stellwagen et al., 2005), the PI-3-K-antagonist blocked the increase in mEPSC-amplitude
of CeA-neurons without the P38-MAP-kinase inhibitor altering this response. Thus, this
finding is consistent with the TNFα-induced increase in amplitude of mEPSCs from CeA
neurons being dependent upon a PI-3-kinase process.
Accompanying the TNFα influence on glutamate function was confirmation that TNFα-
increases the frequency of bicuculline-sensitive mIPSCs (Knapp et al., 2011). This
observation was extended by demonstrating that this increase in mIPSC frequency by TNFα
was dose-dependent and was not accompanied by a change in mIPSC amplitude. Thus,
while TNFα elevates GABA-release, it does not influence post-synaptic sensitivity to
GABA. An issue to be explored in the future is whether facilitation of GABA function by
TNFα has any relation to the degree to which TNFα increases neural activity of CeA
neurons (Knapp et al., 2011). Regardless, this increased frequency of mIPSCs from CeA
neurons induced by TNFα is contrary to the reported reduction in mIPSC-frequency induced
by TNFα from hippocampal neurons (Stellwagen et al., 2005) and the TNFα-induced
increase in synaptic GABAA receptors on spinal-cord neurons (Stück et al. (2012). These
reported differences between brain regions suggest that TNFα may have distinct effects on
GABA function depending upon the brain region investigated—an aspect that should be
explored further.
Based upon previous findings that systemic administration of a CRFR-antagonist prevented
the in vivo action of stress and TNFα to facilitate ethanol-withdrawal anxiety (Breese et al.,
2004; Knapp et al., 2011), the present study examined whether a CRFR-antagonist would
influence any of the neural actions induced by TNFα. Of particular note is that the action of
a general CRFR-antagonist did not alter the TNFα-induced increase in amplitude of
mEPSCs or the reduced current injection required to induce spiking—both measures being
related to glutamate function. In contrast to this lack of effect of the CRFR-antagonist on
these measures of glutamate function, the general CRFR-antagonist and a CRF1R-antagonist
prevented the TNFα-induced increase in mIPSC-frequency, whereas the CRF2R-antagonist
was ineffective in preventing this TNFα-induced change. Hence, this experimental series
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provides evidence that CRF acts on a CRF1R to elevate the frequency of the mIPSCs
induced by TNFα—a finding consistent with the demonstration that CRF applied to CeA
neurons increases the frequency of mIPSCs (Roberto et al., 2010). Consequently, the
CRF1R-antagonist blockade of the increased frequency of mIPSCs induced by TNFα is
compatible with TNFα increasing a CRF synaptic presence that influences CRF-receptors to
increase GABA release (see Roberto et al., 2010). Interestingly, while the CRFR-antagonists
blocked the ability of TNFα to increase mIPSCs, the CRFR-antagonist had no effect on
mIPSCs in the absence of TNFα. This latter finding indicates that under the present
conditions ambient levels of CRF were not sufficient to influence GABA release (mIPSCs).
The involvement of CRF in the increased mIPSC frequency in the CeA may explain why
TNFα does not increase GABA release in all brain regions (see Stellwagen et al., 2005). An
assessment for the future is whether the CRF1R-antagonist blockade of the TNFα-induced
increase in mIPSCs has any relationship to CRF1Rs supporting stress and cytokine
facilitation of ethanol-withdrawal anxiety (Breese et al., 2004, 2008; Knapp et al., 2011).
While the data collected with the CRFR-antagonists provide convincing evidence that CRF
is involved in the TNF-induced increase in frequency of mIPSCs from CeA neurons, the
mechanism for this CRF involvement in the presence of tetrodotoxin (TTX) was open to
clarification. Because the presence of TTX logically eliminates TNFα from stimulating
action-potentials to release CRF from neurons to increase mIPSC-frequency, one possible
explanation considered for this present outcome was that the CRFR-antagonists prevent the
TNFα–induced increase in frequency of mIPSCs by blocking the action of CRF released
from cells other than neurons. Consistent with this latter possibility is the demonstration that
astrocytes are reported to contain CRF (Tian and Bishop, 2003) as well as CRF-binding
protein (Maciejewski et al., 1996; McClennen and Seasholtz, 1999). Further, a number of
other peptides and/or their mRNAs have been localized in a variety of glial cell types
including astrocytes (Ubink et al., 2003). Based upon the concept induced by Santello et al.
(2011; 2012) that TNFα can enhance the abilty of astrocytes to release transmitter, it was
reasoned that TNFα acting on TNFα-receptors on astrocytes or other glial elements (Yan et
al., 2008), reported to contain CRF (Tian and Bishop, 2003), might be involved in making
CRF available to account for the CRFR-antagonists preventing the TNFα-induced frequency
increase in mIPSCs. Whereas this potential influence of TNFα on glia to influence CRF
availability could be either direct or indirect (Santello et al., 2011), in either case glia would
be involved in this action of TNFα.
Because minocycline can disrupt activation of microglia and astrocytes (McAllister and
Miller, 2010), brain slices were pre-incubated with minocycline to test if the TNFα-induced
increase in mIPSC-frequency would be affected. Following minocycline exposure, TNFα
did not cause a significant increase in the mIPSC-frequency. Therefore, TNFα activation of
astrocytes to initiate release CRF could be a part of the mechanism by which CRF is
involved in the TNFα-induced increase in frequency of mIPSCs—a finding consistent with
the many other peptides reported to be present in astrocytes (see Ubink et al., 2003). This
potential involvement of CRF release from glia supporting the TNFα-induced increase in
mIPSCs is illustrated in Fig. 8.
In conclusion, the present electrophysiological studies provide convincing evidence that
TNFα is capable of having an effect on neural function in the CeA. Because CCL2 has also
been demonstrated to increase firing of CeA neurons (unpublished data), it would appear
that cytokines in general may have the capability of influencing neural function in this brain
site. Furthermore, the means by which TNFα increases the amplitude of mEPSCs was
addressed. The present study did not find an effect of a CRFR-antagonist on induction of
action-potentials by current injection, even though it blocked the effect of TNFα on GABA
release in the CeA. A mechanism by which the CRFR-antagonist blocked the TNFα-induced
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increase in frequency of mIPSCs led to evidence with minocycline that CRF may be
released from glia. Nonetheless, as intriguing as the present minocycline results are for
implicating glial involvement of CRF in TNFα action on mIPSCs, one must consider that
minocycline has other actions that might account for this drug preventing the increase in
GABA release induced by TNFα (see Soczynska et al., 2012).
Even though cytokines released by stress in brain have the capability of influencing neural
function, it has yet to be determined how stress in a “sterile” environment (i.e., in the
absence of infection) can increase these cytokines in brain. This latter aspect too must be
addressed before the full impact of stress in relation to cytokine influences on neural
function is understood. The means by which cytokines are involved in stress is important
because cytokines and stress are implicated in pain (Fu and Neugebauer, 2008; Vachon-
Presseau et al., 2013; Watkins et al., 2001), sleep (Krueger et al., 2007; Churchill et al
2008), depression (Caspi et al., 2003; Hammen, 2005), anxiety (Breese et al., 2008; Shin and
Liberzon, 2010) and drug addiction (Breese et al., 2011; Koob, 2008). A further
understanding of the unknowns by which cytokines contribute to stress to alter neural
function may allow a better appreciation of the complexity by which stress induces changes
in neural transmission that contribute to the functional changes associated with stress-linked
central disorders.
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Figure 1. TNFα increased the Amplitude of mEPSCs in CeA
(A) Representative mEPSC recordings from the same neuron in the presence of 20 μM
bicuculline (Control), and after TNFα (TNFα). Application of glutamate antagonists to that
neuron (CNQX + AP-5) blocked the mEPSCs. The glutamate antagonist treatment
completely blocked the mEPSCs in other neurons (n=5). (B) Averaged traces of mEPSCs
from the same neuron in Fig. 1A prior (control) and in the presence of TNFα (60 ng/ml)
showing the increase in mEPSC amplitude induced by TNFα (TNFα). (C) TNFα
concentration enhanced the amplitude of mEPSCs concentration-dependently (n=5–8 for
individual concentrations; F (4,24) = 12.30, p<0.0001) with a significant linear trend;
r(29)=0.74, p<0.05. (D) TNFα did not to influence the frequency of mEPSCs [F
(4,26)=0.22; p>0.05; n=5–8].
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Figure 2. TNFα Reduced the Threshold for current injection to elicit Action-Potentials in CeA
Shown in the upper of figures, are (A) potential traces recorded under control conditions and
(B) traces obtained from the same neuron after a 5-min treatment with 60-ng/ml TNFα. The
injected current was increased by 100 pA with each presentation and traces for the highest
subthreshold current and the threshold current are shown. Threshold current was 600 pA in
(A) and 400pA in (B). (C) TNFα 60-ng/ml lowered the current required to trigger an action
potential [t (6)=3.59, n=7, p<0.05]. (D) When TNFα (60-ng/ml) was applied in the presence
of 10 μM CNQX and 50 μM AP-5, the current threshold for eliciting an action potential did
not change [t(5)=0.93; n=6, p>0.05].
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Figure 3. Blockade of the TNFα-induced increase in mEPSC-amplitude by wortmannin (a PI-3-
K inhibitor)
Shown are percent changes in amplitude of mEPSCs after TNFα (60-ng/ml) (TNFα), TNFα
(60 ng/ml) with 1 μM wortmannin (WMN) incubation for 30-minutes (TNFα + WMN), and
TNFα (60 ng/ml) with 0.1% DMSO incubation for 30 minutes (TNFα + DMSO; a control).
For all treatments, F(2,16) = 5.07, p < 0.05; n = 6–7. Post hoc LSD test shows that the
percent change of the mEPSC-amplitude by TNFα. TNFα + WMN-exposure is significantly
less than the change in amplitude after TNFα alone (p<0.05) and the TNFα with DMSO
(p<0.05).
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Figure 4. TNFα-Induced an Increase in the Frequency of mIPSCs from CeA Neurons
(A) Representative mIPSC recording from a neuron in CeA before (control) and during
(TNFα) application of TNFα (60 ng/ml) in the presence of 1 μM TTX, 10 μM CNQX and
50 μM AP-5. The bottom current trace shows that 20 μM bicuculline completely blocked
these miniature currents, indicating that they were GABAergic. (B) TNFα concentration
dependently [r (38) = 0.51; p < 0.05] increased the frequency of mIPSCs [n = 5–10 for
individual concentrations, one way ANOVA, F (4, 33) = 3.06, p < 0.05]. (C) TNFα did not
to change the amplitude of the mIPSCs [F (4,30) = 0.44; p > 0.05; n = 5–10].
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Figure 5. CRF Receptor (CRFR) Antagonists prevented the TNFα-induced increase in frequency
of mIPSCs
(A) Histograms depicting the percent changes in mIPSCs during applications of 0 (control),
60-ng/ml TNFα and TNFα (60-ng/ml) with the non- specific CRF receptor blocker, α-
helical CRF 9–41 (αHCRF, 1 μM). Over all the percent changes by the three treatments are
significantly different [n=6–8 for individual treatments; F (2, 20)=9.89, p<0.01]. Compared
with control, TNFα increased the frequency of mIPSCs (post hoc, LSD test, p < 0.01) while
α-helical CRF blocked the effects of TNFα (post hoc, LSD test, p<0.001). (B) Shown are
Histograms depicting the TNFα (60 ng/ml) induced increase in frequency of mIPSCs and
either a CRF-2- receptor- (TNFα+Ast) or a CRF-1-receptor- (TNFα+NBI) antagonist on this
TNFα (60-ng/mL)-induced increase in frequency of mIPSCs. Treatments altered modulation
of mIPSCs [n = 6–7 for individual treatments; F (2,17)=5.85, p < 0.05]. While astressin 2B
(100 nM) did not have effects on the function of TNFα (post hoc, LSD test no difference
between TNFα and TNFα with astressin 2B, p>0.05), NBI 27914 (500 nM) blocked the
effects of TNFα (post hoc, TNFα with NBI 27914 significantly less than either TNFα or
TNFα with astressin 2B, p<0.01 and p<0.05, respectively). (C) Miniature IPSCs recording
before (control) and during application of TNFα (60-ng/ml). Note increase in mIPSC
frequency by TNFα. (D) Miniature IPSCs recording before (control) and during application
of 60-ng/ml TNFα with 500 nM NBI 27914. In the presence of the CRF1RA, TNFα did not
increase frequency of mIPSCs.
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Figure 6. CRF-receptor (CRFR)-antagonists did not modulate the effect of TNFα on the current-
injection threshold for eliciting an action potential or the amplitude of mEPSCs From CeA
Neurons
(A) TNFα 30-ng/ml lowered the threshold for current- induced action-potentials [n=7, t
(6)=3.34, p<0.05]. (B) In the presence of α-helical CRF, TNFα 30-ng/ml continued to lower
the threshold current for initiating action-potentials [t (9)=2.57, n=10, p<0.05]. (C) TNFα
30-ng/ml increased in the amplitude of mEPSCs [t (7)=4.67, n=8, p<0.01]. (D) In the
presence of α-helical CRF, TNFα 30-ng/ml continued to increase the amplitude of mEPSCs
[t (7)=3.07, n=8, p<0.05].
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Fig. 7. Effect of Minocycline on the TNFα-induced Increase in mIPSCs from CeA Neurons
The change in frequency of mIPSCs are shown after 60-ng/ml TNFα (TNFα), −60-ng/ml
TNFα with one hour incubation of 60-μM minocycline (TNFα + MNC) and 60-μM
moncycline incubation in the absence of TNFα (MNC). The frequency of mIPSCs was
affected by the minocycline treatment [n =7–13; F(2,24)=4.17, p<0.05]. The percent change
in frequency of mIPSCs induced by TNFα alone is significantly greater than the change
following MNC incubation with TNFα and MNC incubation alone (without TNFα) (p<0.01
and p<0.05, respectively).
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Fig. 8. Possible mechanism of TNFα-induced-CRF-dependent GABA release
As noted, TNFα could act on a glial cell to induce glial release of CRF. This is consistent
with the TNFα-induced release of GABA being blocked either by blocking glial activation
with minocycline or by blocking the effect of CRF at its receptor on the presynaptic terminal
with a CRF-1-antagonist [X]. Noted is that TNFα also acts on the post-synaptic neuron to
activate the PI-3-K to allow amplitude of mEPSCs to be increased (Fig. 3)
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